Biotech Essentials

Biotech & Healthcare

Biotech Healthcare Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 06.07.2021.

#stocks
#biotech
#sclerosis
#Parkinsons
#Alzheimers
#dementia
#cancer
#Aduhelm

Healthcare

@emilylmullin shared
On Jul 1, 2021
“Most of the proposals I’ve heard involving gene drives have seemed quite attractive, and this is probably the most attractive,” says George Church on @erlichya's idea to use gene drives to block coronavirus infections in bats. https://t.co/Jam0uxUSKn
Open
Could editing the genomes of bats prevent future coronavirus pandemics? Two scientists think it’s worth a try

Could editing the genomes of bats prevent future coronavirus pandemics? Two scientists think it’s worth a try

This appears to be the first time that scientists have proposed using the still-nascent gene drive technology to stop coronavirus outbreaks.

@SWLifeSciences shared
On Jul 3, 2021
Alector Partners with GSK to Develop Monoclonal Antibodies for Neurodegenerative Diseases: https://t.co/mfAgukEwUY $ALEC $GSK #biotech #dementia #sclerosis #Parkinsons #Alzheimers #stocks https://t.co/6LDuXP1KvZ
Open
Alector Partners with GSK to Develop Monoclonal Antibodies for Neurodegenerative Diseases

Alector Partners with GSK to Develop Monoclonal Antibodies for Neurodegenerative Diseases

Alector Inc. shares traded 59% higher after the company announced it entered into a global collaboration agreement with GlaxoSmithKline to develop and advance two first-in-class, clinical ...

@CR_UK shared
On Jul 2, 2021
The NHS has been advised that booster vaccines will help maintain protection against COVID-19, and new variants of the virus, for those most at risk. Check our latest update for more information. https://t.co/1lVajwhghR
Open
COVID-19 vaccine and cancer – latest updates

COVID-19 vaccine and cancer – latest updates

Recently, news of a COVID-19 vaccine has dominated headlines. We've summarised all the information that is out there, with rolling updates, in our new vaccine blog post.

@SWLifeSciences shared
On Jun 30, 2021
Biotech Takes a 'Disruptive Drug Development Approach' to Destroy Dysregulated Transcription in Cancer: https://t.co/hNTqLI0HgP Kronos Bio's key assets are reviewed in an H.C. Wainwright & Co. report. $KRON #biotech #cancer #stocks @KronosBio https://t.co/9Mvt5wR2ra
Open
@Synteract shared
On Jul 4, 2021
Halfway through the year...here's what's happened so far. https://t.co/rS5xQZFwFm
Open
Top 10 Healthcare IT News stories of 2021 so far

Top 10 Healthcare IT News stories of 2021 so far

Believe it or not, we're already halfway through the year. Here's what HITN readers have been clicking.

@BIODeutschland shared
On Jul 1, 2021
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease https://t.co/ST84jlHxem
Open
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease

Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease

Freiburg and Darmstadt, July 1st, 2021 Dr. Falk Pharma GmbH and Zedira announce successful completion of the phase 2a clinical trial of ZED1227, a direct-acting and specific …

@NatureBiotech shared
On Jun 30, 2021
Not only do 87% of US-based docs and 89% of neurologists disagree with #Aduhelm's approval @Medscape https://t.co/wn0cjmkJ0P but also 80% of biopharma execs @endpts https://t.co/zkatV5u3cM. See our editorial on the drug https://t.co/f2qKhHbfsv https://t.co/qDFKOomQdO
Open
What does a clear majority of the biopharma industry think of the FDA approval of aducanumab? 'Horrifying' 'Dangerous' 'Confusing' 'Disaster'

What does a clear majority of the biopharma industry think of the FDA approval of aducanumab? 'Horrifying' 'Dangerous' 'Confusing' 'Disaster'

Over the years, we’ve become used to seeing a consensus emerge early in our industry polls at Endpoints News. And when we took the pulse of drug hunters on the heels of a controversial FDA ...